Comments
More from the author
Curated and popular this week
73
TL;DR
* GOAL 3 is a social enterprise that created IMPALA, a patient monitoring and digital platform system for low-resource settings. There is also a GOAL 3 foundation that raises funds to ensure underserved communities will be reached.
* A recently completed report from Rethink Priorities calculated IMPALA to have a cost per DALY averted of $7–17 in paediatr...
This month effective altruism has gotten lots of attention, including a cover story in The Economist. It feels pretty surreal to be on the receiving end of it. But I feel grateful these ideas have caught on, and even more grateful for the drive, earnestness, and compassion of so many people who took strange but well-argued ideas seriously and then actually acted on them....
Impressions from the 21st Annual U.S. Cluster Headache Patient Conference, organized by Clusterbusters.
On the morning of the last day of the conference, E. was hanging out with other “clusterheads” outside the conference hotel when he started having a cluster headache attack. Before he could go back to his hotel room, J. offered E. his DMT v...
Recent opportunities to take action
In your view, what is the next step?
This has some of 1Day's thoughts (though it was published before PQ happened). This tweet thread is briefer and has some more technical ideas.
Big picture -- probably need to raise about $500 million to pay for distribution and need to get WHO/GAVI/UNICEF to announce a much more aggressive plan for implementation. Also need to do a ton of work in African countries to create the political will and technical plans for rapid rollout.
From an advocacy perspective, 1Day's main idea is to generate a ton of public attention to achieve the goals above (particularly the money) -- ideally by bringing in new philanthropic funders, though that may be unrealistic. But there will also be more targeted campaigns at the international institution and African country levels.
Current rollout plans are unclear, but the below probably gives the best sense of current international institution goals.
As you can see, current vision doesn't get to the predicted steady state (80 million doses) until about 2027. Serum Institute can currently produce 100 million doses per year and already has on-hand material to make 20 million. About 80 million children are at risk of malaria and in the age range in which R21 was tested and demonstrated high efficacy. About 25 million are born each year. Each child requires 4 doses (3 doses the first year followed by a booster).
Optimistically, Gavi and partners do their thing and we get a nice efficient rollout across the relevant areas. But I have very limited knowledge of this space. I don't know what the bottlenecks or process here is.